Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.

PURPOSE The aim of the current study is to compare the effects of two corticosteroids, prednisolone acetate 1% (PA) and loteprednol etabonate 0.5% (LE), for the treatment of benzalkonium chloride (BAC)-induced dry eye syndrome (DES) in rats. METHODS DES was established by topical administration of 0.2% BAC, a commonly used preservative in ophthalmic drugs, for 1 week. Rats were divided into 3 groups just after establishment of DES: PA-treated (Group 1, n=10), LE-treated (Group 2, n=10), and vehicle-treated (Group 3, n=10). Rats were treated by topical administration of PA, LE, or vehicle twice daily for 1 week. The Schirmer test, break-up time score, Fluorescein staining, Rose Bengal staining, and inflammatory index scoring (IIS) tests were performed at all weeks. After the end of the study, eyes of the rats were enucleated and analyzed using light microscopy. RESULTS The mean aqueous tear volume was significantly increased in both PA- and LE-treated rats (P<0.05), although decreased in vehicle-treated rats (P>0.05). Histologically, diffuse inflammatory cell infiltration was observed in vehicle-treated rats, while inflammation induced by BAC was almost completely resolved in both PA- and LE-treated groups. CONCLUSIONS In the current study, we showed that both PA and LE are effective treatments in a rat model of BAC-induced DES, which is commonly observed in clinics. No significant differences were observed between the 2 corticosteroids in the efficacy of BAC-induced type of DES treatment.

[1]  P. Hamrah,et al.  In Vivo Confocal Microscopy in Dry Eye Disease and Related Conditions , 2012, Seminars in ophthalmology.

[2]  C. Joo,et al.  Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. , 2012, Investigative ophthalmology & visual science.

[3]  R. Chuck,et al.  Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulium toxin B-induced murine dry eye model , 2012, Molecular vision.

[4]  F. Eperjesi,et al.  Evaluation of dry eye. , 2012, Survey of ophthalmology.

[5]  B. Yavuz,et al.  An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery , 2012, TheScientificWorldJournal.

[6]  T. Comstock,et al.  Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate , 2012, International journal of inflammation.

[7]  Chaoyang Li,et al.  Research on the Stability of a Rabbit Dry Eye Model Induced by Topical Application of the Preservative Benzalkonium Chloride , 2012, PloS one.

[8]  K. Tsubota,et al.  The international workshop on meibomian gland dysfunction: executive summary. , 2011, Investigative ophthalmology & visual science.

[9]  Zuguo Liu,et al.  A mouse dry eye model induced by topical administration of benzalkonium chloride , 2011, Molecular vision.

[10]  Michael E. Stern,et al.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease , 2010, Molecular vision.

[11]  J. Proksch,et al.  Ocular Pharmacokinetics of Loteprednol Etabonate Following Ocular Administration of a Novel Ointment Formulation or a Suspension (Lotemax®) in Rabbits With Corneal Inflammation , 2010 .

[12]  Srihari Narayanan,et al.  Advancements in anti-inflammatory therapy for dry eye syndrome. , 2009, Optometry.

[13]  İ. Meteoğlu,et al.  Effects of long-term passive smoking on vascular endothelial growth factor and apoptosis markers expression in lens and corneal epithelial cells: An experimental study* , 2009, Turkish Journal of Medical Sciences.

[14]  S. Pflugfelder,et al.  Rationale for anti-inflammatory therapy in dry eye syndrome. , 2008, Arquivos brasileiros de oftalmologia.

[15]  Jian Ge,et al.  A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. , 2008, Investigative ophthalmology & visual science.

[16]  S. Pflugfelder.  Prevalence, burden, and pharmacoeconomics of dry eye disease. , 2008, The American journal of managed care.

[17]  J. Qu,et al.  A murine model of dry eye induced by an intelligently controlled environmental system. , 2008, Investigative ophthalmology & visual science.

[18]  C. Baudouin,et al.  New tools for the evaluation of toxic ocular surface changes in the rat. , 2007, Investigative ophthalmology & visual science.

[19]  R. Chuck,et al.  Comparison of Topical Dry Eye Medications for the Treatment of Keratoconjunctivitis Sicca in a Botulinum Toxin B-Induced Mouse Model , 2007, Cornea.

[20]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[21]  De-Quan Li,et al.  Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.

[22]  De-Quan Li,et al.  Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. , 2006, Investigative ophthalmology & visual science.

[23]  J. Yanni,et al.  Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[24]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[25]  M. Dana,et al.  Animal models of dry eye: a critical assessment of opportunities and limitations. , 2004, Investigative ophthalmology & visual science.

[26]  S. Pflugfelder.  Antiinflammatory therapy for dry eye. , 2004, American journal of ophthalmology.

[27]  E. Varnell,et al.  The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. , 2003, American journal of ophthalmology.

[28]  G. Foulks.  The evolving treatment of dry eye. , 2003, Ophthalmology clinics of North America.

[29]  S. Pflugfelder.  Anti-inflammatory therapy of dry eye. , 2003, The ocular surface.

[30]  C. Baudouin.  The pathology of dry eye. , 2001, Survey of ophthalmology.

[31]  Sainz De La Maza Serra M,et al.  [Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca]. , 2000, Archivos de la Sociedad Espanola de Oftalmologia.

[32]  S. Pflugfelder,et al.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.

[33]  J. Alió,et al.  Combined non-steroidal therapy in experimental corneal injury. , 1997, Ophthalmic research.

[34]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[35]  J F Howes,et al.  Intraocular pressure response to loteprednol etabonate in known steroid responders. , 1993, Journal of ocular pharmacology.

[36]  N. Bodor,et al.  Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. , 1991, Current eye research.